Influence of the decrease in ciprofloxacin susceptibility and the presence of human serum on the in vitro susceptibility of Streptococcus pneumoniae to five new quinolones

被引:10
作者
Balcabao, IP
Alou, L
Aguilar, L
Gomez-Lus, ML
Giménez, MJ
Prieto, J [1 ]
机构
[1] Univ Complutense Madrid, Sch Med, Dept Microbiol, E-28040 Madrid, Spain
[2] GlaxoSmithKline, Dept Med, Madrid, Spain
关键词
D O I
10.1093/jac/48.6.907
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Sixty recent Streptococcus pneumoniae isolates with different susceptibilities to ciprofloxacin (14 with MIC 0.5 mg/L, 10 with MIC 1 mg/L, eight with MIC 2 mg/L, 11 with MIC 4 mg/L and 17 with MIC greater than or equal to8 mg/L) were tested against five new quinolones using Todd-Hewitt broth with and without 80% serum. The final inoculum was 5 x 10(5) cfu/mL. Gemifloxacin and clinafloxacin exhibited the lowest MIC90 values and resistance rates (percentage above and defined breakpoint) with and without serum for strains with a ciprofloxacin MIC of greater than or equal to4 mg/L. Other quinolones tested were less active against strains with reduced ciprofloxacin susceptibility. The presence of serum did not affect susceptibility to moxifloxacin, but increased the resistance rates to other new quinolones for strains with high ciprofloxacin MICs.
引用
收藏
页码:907 / 909
页数:3
相关论文
共 9 条
[1]  
[Anonymous], M100S11 NCCLS
[2]   Antimicrobial resistance of 1,113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain:: Results of a 1-year (1996-1997) multicenter surveillance study [J].
Baquero, F ;
García-Rodríguez, JA ;
de Lomas, JG ;
Aguilar, L .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (02) :357-359
[3]  
Eliopoulos G M, 1995, Drugs, V49 Suppl 2, P48
[4]  
EWING S, 1999, AM J RESP CRIT CARE, V159, P1835
[5]   In vitro susceptibility to gemifloxacin and trovafloxacin of Streptococcus pneumoniae strains exhibiting decreased susceptibility to ciprofloxacin [J].
Fuentes, F ;
Giménez, MJ ;
Marco, F ;
Alou, L ;
Aguilar, L ;
Prieto, J .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2000, 19 (02) :137-139
[6]   Influences of different factors on prevalence of ciprofloxacin resistance in Streptococcus pneumoniae in spain [J].
García-Rey, C ;
Aguilar, L ;
Baquero, F .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (12) :3481-3482
[7]   Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae [J].
Lister, PD ;
Sanders, CC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (01) :79-86
[8]   Bactericidal activity, morphological alterations, and synergistic interactions of rufloxacin, a new fluoroquinolone, alone and in combination with its N-desmethylate D derivative (MF 922) [J].
Marchese, A ;
Debbia, EA ;
Pesce, A ;
Schito, GC .
CHEMOTHERAPY, 1996, 42 (02) :90-99
[9]   In vitro activity of BAY 12-8039, a new fluoroquinolone [J].
Woodcock, JM ;
Andrews, JM ;
Boswell, FJ ;
Brenwald, NP ;
Wise, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (01) :101-106